Claire E Parker

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2885064/publications.pdf

Version: 2024-02-01

1040056 1281871 11 600 9 11 citations h-index g-index papers 11 11 11 935 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Innovations in Oral Therapies for Inflammatory Bowel Disease. Drugs, 2019, 79, 1321-1335.	10.9	51
2	Targeting anti-fibrotic pathways in Crohn's disease â€" The final frontier?. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2019, 38-39, 101603.	2.4	12
3	What is the role of C-reactive protein and fecal calprotectin in evaluating Crohn's disease activity?. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2019, 38-39, 101602.	2.4	19
4	Identifying Outcomes in Clinical Trials of Pouchitis for the Development of a Core Outcome Set. Clinical Gastroenterology and Hepatology, 2019, 17, 1637-1640.	4.4	3
5	Placebo Rates in Randomized Controlled Trials of Pouchitis Therapy. Digestive Diseases and Sciences, 2018, 63, 2519-2528.	2.3	10
6	Development of a core outcome set for clinical trials in inflammatory bowel disease: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey. BMJ Open, 2017, 7, e016146.	1.9	35
7	Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis. The Cochrane Library, 2017, 9, CD011572.	2.8	13
8	Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. The Cochrane Library, 2016, , CD000544.	2.8	197
9	Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. The Cochrane Library, 2016, 4, CD000543.	2.8	202
10	Efficient EarlyÂDrug Development for Ulcerative Colitis. Gastroenterology, 2016, 150, 1056-1060.	1.3	19
11	Systematic Review and Meta-analysis: Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis. Journal of Crohn's and Colitis, 2016, 10, 607-618.	1.3	39